Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Presynaptic dopaminergic imaging as a neurodegeneration staging biomarker in the alpha-synucleinopathy continuum.

European journal of nuclear medicine and molecular imaging·2026
Same author

Screening for Alzheimer's disease in the community using an AI-driven screening platform: design of the PREDICTOM study.

The journal of prevention of Alzheimer's disease·2026
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Clinical Manifestations.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Public Health.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same journal

Evidence for progressive neurodegeneration in iatrogenic cerebral amyloid angiopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Human brain connectome profiles mediate the relationship between pathology burden and clinical phenotypes in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Kat5 cKO mouse replicates biological domain signatures associated with Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Associations of self-reported obstructive sleep apnea with cognition and dementia risk in cognitively unimpaired middle-aged adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Hadrien M Lalive1, Federica Ribaldi1,2, Augusto J Mendes1,2

  • 1Geneva Memory Center, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 24, 2025
PubMed
概括
此摘要是机器生成的。

大脑粉样血管病变 (CAA) 影响29%的阿尔茨海默病 (AD) 患者,显示出类似的认知功能和AD生物标志物,无论CAA的概率如何. 这凸显了需要在记忆诊所设置中对波士顿标准进行进一步研究的需要.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经学 神经学
  • 神经成像是一种神经成像.
  • 生物标志物 生物标志物

背景情况:

  • 脑粉样蛋白血管病变 (CAA) 诊断对于接受抗粉样蛋白免疫治疗的阿尔茨海默病患者至关重要,因为它与粉样蛋白相关的成像异常有关.
  • 波士顿标准是识别可能的CAA在记忆诊所的标准,但其在认知障碍AD患者的患病率和特征尚未明确.

研究的目的:

  • 用更新的波士顿标准 (v2.0) 确定认知障碍,生物标志物确认的AD患者中CAA的患病率.
  • 为了比较AD患者与没有CAA之间的认知,临床和生物标志物概况.

主要方法:

  • 从一个记忆中心数据库 (2012年6月 - 2024年7月) 追溯分析了415名可能患有AD的患者 (生物标志物确认).
  • 放射科医生和图像分析师 (对临床数据视而不见) 审查了MRI扫描,神经科医生证实了诊断.
  • 使用波士顿标准将患者分为CAA的高 (AD-CAA) 或低 (AD-nCAA) 概率;使用统计测试比较特征.

主要成果:

  • 29%的AD患者被归类为AD-CAA,而71%的患者是AD-nCAA.
  • 认知严重程度,全球认知,口头情节性记忆和执行功能在AD-CAA和AD-nCAA组之间是可比的.
  • AD-CAA患者年龄较大,更有可能使用抗血小板治疗,心血管疾病患病率较高,但心血管风险因素和AD生物标志物概况相似.

结论:

  • 通过波士顿标准确定的AD患者中CAA的患病率低于基于病理学的估计.
  • 在记忆诊所的AD患者可能具有相似的认知特征和AD生物标志物模式,无论他们的CAA概率如何.
  • 进一步的研究对于验证波士顿标准在AD的记忆诊所人群中的应用至关重要.